Urovant Sciences (UROV) Tops Q1 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Urovant Sciences (UROV) Tops Q1 EPS by 40c

Urovant Sciences Reports Fiscal First Quarter 2020 Results

August 13, 2020 4:05 PM EDT

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020.

The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.

We continued to make important progress in the first fiscal quarter of 2020. We significantly enhanced the commercial and market access capabilities we need to successfully... More